Penumbra Inc
PEN: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|#> | LOCK|#& | LOCK|Q<lS!Sl |
Penumbra Earnings: Recent Trial Data Offer Bright Prospects for Strong Growth
Penumbra delivered third-quarter results that featured revenue and net income growth of 17% (in constant currency) and 35%, respectively. The firm recently shared favorable data from its landmark study on computer assisted vacuum thrombectomy, or CAVT, for pulmonary embolism.
